Trial · NCT06903559
Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
NCT06903559, Phase 1, Phase 2, Recruiting, Mansoura University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients. Trials, record NCT06903559. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06903559
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
- NCT number
- NCT06903559
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 46 participants, estimated
- Lead sponsor
- Mansoura University
- Conditions
- Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease, Cardiovascular Diseases (CVD)
- Interventions
- Roxadustat, Conventional Anemia Management
- First posted
- 2025-03-30
- Last updated
- 2025-05-13
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 6 Months | Baseline and 6 months | Assesses the change in the percentage of blood leaving the left ventricle with each contraction, measured by transthoracic echocardiography at the beginning of the study and after 6 months of treatment. An increase indicates improvement in systolic function. |
| Secondary | Change from Baseline in Carotid Intima-Media Thickness (CIMT) at 6 Months | Baseline and 6 months | Assesses the change in the thickness of the inner layers of the carotid artery wall, a marker of atherosclerosis. Measured by Doppler ultrasound of the carotid artery at the beginning of the study and after 6 months of treatment. A decrease or smaller increase indicates less progression of atherosclerosis. |
| Secondary | Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP) Level at 6 Months | Baseline and 6 months | Assesses the change in a marker of systemic inflammation. Measured via laboratory blood test at the beginning of the study and after 6 months of treatment. A decrease indicates reduced inflammation. |
| Secondary | Change from Baseline in Normalized Protein Catabolic Rate (nPCR) at 6 Months | Baseline and 6 months | Assesses the change in protein catabolism, reflecting nutritional status and protein intake adequacy in dialysis patients. Calculated based on urea kinetics (typically from pre- and post-dialysis BUN and dialysis parameters) at the beginning of the study and after 6 months. An increase may indicate improved nutritional status (within appropriate ranges). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06903559
GET https://conductscience.org/api/trials/v1/NCT06903559/registered